REVIEW

Rotavirus Vaccines: a story of success with challenges ahead

[version 1; peer review: 3 approved]

Miguel O'Ryan

Institute of Biomedical Sciences and Millenium Institute of Immunology and Immunotherapy, Faculty of Medicine, University of Chile, Santiago, Chile

V1 First published: 18 Aug 2017, 6(F1000 Faculty Rev):1517
<https://doi.org/10.12688/f1000research.11912.1>

Latest published: 18 Aug 2017, 6(F1000 Faculty Rev):1517
<https://doi.org/10.12688/f1000research.11912.1>

Abstract

Approximately 40 years have passed since the discovery of the rotavirus and 10 years since the introduction and progressive dissemination of rotavirus vaccines worldwide. Currently, 92 countries have introduced rotavirus vaccines into national or subnational programs with evident impact in disease reduction. Two vaccines have been widely used, and four additional vaccines have been licensed and are being used in defined regions. In this context, one main issue that remains unsolved is the lower vaccine efficacy/effectiveness in low-income countries. An additional partially answered issue relates to rotavirus strain circulation in vaccinated populations. These issues are discussed in this review. The most imperative challenge ahead is to fulfill the WHO's recommendation to introduce rotavirus vaccines in all countries.

Keywords

rotavirus, vaccination, gastroenteritis, immunity

Open Peer Review

Approval Status

	1	2	3
version 1 18 Aug 2017			

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Maarten J. Postma**, University of Groningen, Groningen, The Netherlands
Abraham Wondimu Dagne, Mekelle University, Mekelle, Ethiopia
2. **Zulfiqar Bhutta**, The Hospital for Sick Children, Toronto, Canada
3. **Umesh Parashar**, CDC, Atlanta, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Miguel O'Ryan (moryan@med.uchile.cl)

Author roles: O'Ryan M: Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: The author declares that he has no competing interests.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2017 O'Ryan M. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: O'Ryan M. **Rotavirus Vaccines: a story of success with challenges ahead [version 1; peer review: 3 approved]** F1000Research 2017, 6(F1000 Faculty Rev):1517 <https://doi.org/10.12688/f1000research.11912.1>

First published: 18 Aug 2017, 6(F1000 Faculty Rev):1517 <https://doi.org/10.12688/f1000research.11912.1>

Rotavirus disease before the vaccine era

Rotavirus was first visualized in 1973 when electron microscopy was used to examine stools from ill children; subsequently, several decades of epidemiological research concluded that rotavirus was the main cause of acute diarrheal disease in children younger than 5 years of age worldwide^{1–3}. Community- and hospital-based studies performed before 2006, the year current vaccines were licensed, proved that rotavirus was a key player in childhood gastroenteritis, accounting annually for 25 million outpatient medical visits, 2 million hospitalizations, and 400,000 deaths⁴. At the time, best estimates indicated that every child would be infected by 5 years of age, one in 5 would require a medical visit, one in 65 would be hospitalized, and one in 293 would die, mostly children living in poor regions of the world.

Rotavirus vaccines

Vaccine development approach

Rotavirus vaccine development began soon after rotavirus discovery, and some key findings are summarized here:

- i) Cohort- and daycare-based studies, aimed to define the natural history of rotavirus infection, demonstrated that repeated infections were common throughout the first few years of life but that it was the first infection that caused most moderate to severe symptomatic episodes, while subsequent infections tended to be milder or asymptomatic^{5,6}. Thus, previous episodes “protected” against subsequent symptomatic episodes, less against reinfections in general, which could potentially be mimicked by vaccines.
- ii) The discovery that humans could be infected by different rotavirus serotypes (strains that have non-cross-reacting neutralizing epitopes in the external VP7 and/or VP4 capsid when tested in cell culture) became a highly relevant issue during vaccine development. New serotypes are constantly emerging because of genetic reassortment, a process that is constantly occurring between animal and human strains. Nevertheless, over the last 40 years, fewer than 10 serotypes have been the predominant cause of childhood infections, indicating that only a few are fit to infect the human intestine. The predominance of a relatively small number of serotypes varies in an unpredictable manner between different regions and/or different time periods, most likely due to population-related immunity⁷. From the 1970s to 1990s, a key question was what role serotype variability would play in vaccine protection. The fact that one antigenic serotype (for example, VP7 type G1), when inoculated into mice, did not elicit robust neutralizing antibodies inhibiting growth in cell culture of a virus with a different VP7 epitope (G2, G3, G4, or other) led to the concept of “homotypic immunity”, promoting a development strategy based on “multi antigenic component vaccines”⁸. Child cohort studies, on the other hand, suggested that a multivalent vaccine approach could be avoided, as most children had at most one moderate to severe rotavirus infection, irrespective of the antigenic types to which they were exposed over the years⁵. This observation promoted a vaccine strategy based on “heterotypic immunity”, where a single human attenuated

strain could confer protection against different serotypes possibly by humoral and/or cellular-mediated processes other than VP7- or VP4-specific neutralizing epitopes^{9,10}.

- iii) Several humoral biomarkers have been correlated with protection against infection and disease in child cohorts evaluating natural infections and/or in early vaccine trials (serum and/or stool serotype-specific neutralizing antibodies, total IgA and IgG non-neutralizing RV-specific antibodies, and RV-secretory IgG and RV-specific T cells in animal models)¹¹. Consensus as to the specific protective levels of any of the above-mentioned biomarkers, suitable for use as a proxy for clinical protection, was not reached at the time and has not been reached to date. The lack of a biomarker obliged researchers to move forward with large efficacy trials based on clinical variables, of which moderate to severe rotavirus-positive diarrheal disease became the hallmark.

Currently licensed vaccines

The multi antigenic component vaccine strategy based on animal-human reassortant strains was strongly promoted by scientists from the NIH, such as Al Kapikian, the “founding father” of rotavirus. This strategy led the vaccine development race during the 1990s, culminating in 1998 with the US licensing of the first vaccine, RotaShield®, a quadrivalent human-rhesus reassortant vaccine produced by Wyeth Lederle¹² (Table 1). Vaccine efficacy studies had been promising, indicating protective rates ranging from 70 to 90% against moderate to severe gastroenteritis, measured by clinical scores including variables such as intensity and duration of diarrhea, severity of dehydration, fever, vomiting, and hospitalization^{13–16}. Quite to the surprise of the rotavirus community, an early signal that the vaccine was associated with intestinal intussusception, an uncommon but severe event where the proximal jejunum telescopes into the distal portion causing acute intestinal obstruction, was confirmed after 12 months of vaccine use in the United States¹⁷. Pre-licensure trials had hinted at the possibility; however, the studies were not sufficiently powered to demonstrate an increased risk, which was finally estimated to occur in roughly one out of every 4,670–9,474 vaccinated infants. The manufacturers withdrew RotaShield® and 8 years of further research were required before new vaccines reached licensing.

The vaccine race continued between two new candidates: 1) RotaTeq®, a multi antigenic component vaccine including five bovine-human reassortant strains, and 2) Rotarix®, a human attenuated single strain. Both candidates published their landmark phase III trial results in the same issue of *The New England Journal of Medicine* in January 2006^{18,19}. The efficacy of both vaccines against moderate to severe disease in middle- to middle-high-income countries, based on different clinical scores, surpassed 85%, and although many intended to advance efficacy comparisons, especially efficacy against different rotavirus serotypes, this was not possible, as a number of variables differed between the trials, including populations studied and primary and secondary endpoints. Unfortunately, comparative studies have not been performed to date. Importantly, pre-licensure efficacy and post-licensure effectiveness studies in developing countries have demonstrated that both vaccines are only about 50–60% efficacious against severe diseases,

Table 1. Licensed vaccines and vaccine candidates in clinical phases of development.

Vaccine	Status	Comments	Selected references
RotaTeq®/Rotarix®	Worldwide license	Eleven years' post-licensure; worldwide distribution; demonstrated effectiveness	Giaquinto <i>et al.</i> ⁶⁷ ; O'Ryan <i>et al.</i> ²⁰
Rotashield®	First licensed rotavirus vaccine in 1998 (USA); was withdrawn due to association with intestinal intussusception	Underwent a clinical trial with a two-dose regimen beginning within the first 30 days of life demonstrating 63% efficacy for the first 12 months of life	Armah <i>et al.</i> ⁶⁸
LLR®/Rotavin-M1®/Rotavac®	Restricted license	Only used in China/Vietnam/India (respectively); lack of robust effectiveness data	Fu <i>et al.</i> ³² ; Dang <i>et al.</i> ³⁴ ; Bhandari <i>et al.</i> ⁶⁹
UK reassortant (Rotasiil®)	Restricted license	Phase III study	Isanaka <i>et al.</i> ³⁶
RV3BB	Early clinical development	Phase I or early phase II studies	Danchin <i>et al.</i> ⁷⁰ ; Luna <i>et al.</i> ⁷¹ ; Bines <i>et al.</i> ³⁸ ; Naik <i>et al.</i> ³⁵
Truncated VP8 subunit and a tetanus toxoid P2 protein	Early clinical development	Phase I/II study	Groome <i>et al.</i> ³⁹

Adapted from 72

indicating that socioeconomic factors play a role^{20,21}. Neither of the vaccines hinted at the possibility of an association with intussusception similar to RotaShield® in large clinical trials; these trials enrolled over 60,000 subjects, the sample size required to identify a 1:10,000 risk of intussusception. Nevertheless, post-licensure studies have demonstrated that both vaccines are associated with intussusception at a risk range of 1:20,000 to 1:100,000, a rate of risk that is considered a “class effect”^{22,23}. The overall estimate of relative risk of intussusception in the 7 days following vaccination with Rotarix® and RotaTeq® was 5.4 and 5.5, respectively, following the first dose, and 1.8 and 1.7, respectively, following the second dose. The relative risk estimates were approximately tenfold lower than those reported for RotaShield®²⁴. This suggests that in a very small number of infants, possibly at increased risk for yet-undiscovered reasons for intussusception, the event may be triggered by vaccination, especially if the first dose is provided later into the first 6 months of life. This low risk needs to be acknowledged, although most recommending bodies clearly express that the benefits of rotavirus gastroenteritis prevention by far outweigh the low-level risk of intussusception, regardless of the geographic region in which the child lives^{25–29}.

Four additional rotavirus vaccines, similar to RotaTeq® or Rotarix®, have been licensed: 1) Rotavac® and 2) Rotasiil® which are licensed by local manufacturers in India, with phase I–III supporting trials, 3) Lanzhou Lamb vaccine in China, and 4) Rotavin-MI® in Vietnam. The latter two vaccines were licensed with significantly fewer studies. Rotavac® includes the neonatal 116E rotavirus strain, a naturally occurring human-bovine reassortant strain of the G9P [11] serotype³⁰. In a phase III trial of nearly 7,000 Indian infants, protective efficacy against moderate to severe gastroenteritis of a three-dose regimen at 12 months of age was 56%³¹. The Lanzhou Lamb vaccine, based on a rotavirus strain obtained in 1985 from a local lamb with diarrhea and attenuated through serial passages³²,

was licensed in China in 2000. Despite the lack of studies on clinical efficacy and safety, over 30 million Chinese children under 5 years of age have been immunized using a schedule that includes a first dose for children 2 months to 3 years of age followed by annual boosters for up to four doses by 5 years of age. Effectiveness against rotavirus hospitalization seems to be around 60 to 78%^{32,33}. Rotavin-MI® is similar to Rotarix® in that it is a G1P [8] attenuated strain obtained from a Vietnamese child. There is only one available published study on this vaccine that includes evaluations of different virus concentrations and doses in a phase I adult-infant and phase II infant trials³⁴. Rotasiil® is a UK bovine reassortant vaccine composed of five reassorted strains, with the added benefit of heat stability, developed in partnership with researchers from the USA, India, and Brazil³⁵. In Nigerian children, three doses had an efficacy of 67% against severe rotavirus gastroenteritis³⁶. Yet another vaccine, this time a quadrivalent vaccine, produced by Shantha Biologicals of India using the same bovine backbone strain, did not meet immunogenicity non-inferiority compared to the pentavalent vaccine, as anti-rotavirus IgA seroconversion was only 47% compared to 61%³⁷. A neonatal strain, RV3BB, developed by Australian researchers recently demonstrated a reasonable immune response in a rather small study; vaccine take occurred after three doses, regardless of whether the first dose was provided at 0–5 days or 8 weeks of life³⁸.

The only candidate based on an alternative strategy that has reached clinical trials is based on a truncated VP8 subunit protein of the human Wa strain and a tetanus toxoid P2 protein. In a phase I/II trial in children, immunogenicity against the homotypic antigen was high after three intramuscular doses but was significantly lower against heterotypic antigens, suggesting that this strategy will require a multicomponent approach³⁹. Interestingly, the vaccine had the effect of reducing subsequent live oral rotavirus vaccine shedding, suggesting some impact at the intestinal level⁴⁰.

Rotavirus burden 10 years after rotavirus vaccine licensing

It is estimated that in 2015 there were nearly 2.4 billion episodes of acute diarrhea, of which nearly 950 million occurred in children younger than 5 years of age. In the same year, diarrheal diseases were responsible for nearly 1.31 million deaths, of which nearly 500,000 occurred in children under 5 years of age. Rotavirus was estimated to cause nearly 147,000 deaths. Between 2005 and 2015, the number of diarrhea cases in children under 5 years of age decreased by about 10%, and deaths due to diarrhea decreased by around 34%, while rotavirus deaths decreased by 44% (95% CI: 33–52%)⁴¹. Attribution of this reduction in rotavirus cases and deaths to vaccine use is difficult, especially because vaccines are not widely used in the countries with the highest disease burden; nevertheless, rotavirus vaccines have most likely played an important role. As of January 2017, 92 countries have introduced rotavirus vaccines. This includes 85 national introductions, two ongoing phased introductions, and five subnational introductions (<http://rotacouncil.org/vaccine-introduction/global-introduction-status/>). A dramatic decrease (>80%) in the incidence of severe rotavirus diarrhea has been reported in high-income countries, and a decrease of about 50% has been reported in low-income settings³³. Increasingly, evidence shows reductions in diarrhea-associated deaths of 31% in infants younger than 1 year old and 42% in children younger than 5 years old in countries with low child mortality⁴². Specific data from low-income countries, where childhood mortality and specifically diarrhea-associated mortality is highest, are scarce. In South African children receiving two vaccine doses, Groome and colleagues showed 57% (95% CI: 40–68) effectiveness for rotavirus diarrhea requiring at least overnight hospital admission in children younger than 2 years of age⁴³. In Malawi children receiving two doses in an accelerated schedule, Naor Bar-Zeev and colleagues showed 64% (95% CI: 24–83) effectiveness for reduction of rotavirus-positive emergency room visits (compared with rotavirus test-negative controls) in children younger than 5 years old (94% of samples tested from children younger than 2 years of age)^{44,45}. Furthermore, and most importantly, rotavirus vaccines have not been implemented in countries with the highest rotavirus-associated disease burden. Nearly 40% of sub-Saharan Africa and almost all South-East Asia (with the exception of India and Pakistan, where vaccines are being introduced in a phased format) have not yet introduced rotavirus vaccines.

Challenges ahead

The most imperative current and future challenge is to fulfill the WHO's recommendation to introduce rotavirus vaccines in all countries, with no exceptions. Funding and support priorities should and are being placed in countries with the highest mortality rates⁴⁶. Unfortunately, in many instances, a lack of funding is not the only limitation to implementation in these countries; there is also a lack of political will and/or recognition of the potential benefits of vaccination. In too many middle-income countries, where diarrhea-associated deaths are uncommon but where rotavirus-associated medical and emergency room visits and hospitalizations are significant, health authorities frequently fail to recognize the need for rotavirus vaccines. Increasing the importance of technical advisory groups, including the use of efficient decision-making tools (such as the Grading of Recommendations, Assessment, Development and Evaluations [GRADE]^{47,48}), would help balance the viewpoints of health and financial authorities.

Live attenuated rotavirus vaccines have worked well, but we cannot consider current protection levels to be optimal. Unfortunately, efficacy and effectiveness decrease inversely with poverty. The reasons behind this phenomenon are not clear, but there is indirect evidence supporting several possibilities. Firstly, rotavirus infections occurred at younger ages and repeated symptomatic infections were more common in a birth cohort from a very poor area in India compared to a less-deprived area in Mexico^{5,49}. This observation strongly suggests that viral exposure is significantly higher in poorer regions, most likely due to increased exposure to human feces. Vaccination at earlier ages, more doses, and/or higher dose concentrations may benefit such populations, but a significant increase in protection, from 50–60% to 80–90%, seems unlikely unless there is a concurrent improvement in environmental sanitation. Secondly, the co-administration of oral polio, more commonly used in developing countries, and rotavirus vaccines reduces the immune response to the latter, which most likely has some impact on reduced vaccine efficacy/effectiveness⁵⁰. A third factor may be increased incidence of breastfeeding in low-income areas. While breastfeeding did not significantly reduce the immunogenicity of rotavirus vaccine in Finnish children, it was associated with a mild decrease in protection, especially during the second year of life⁵¹. Mexican researchers demonstrated that breastfeeding can interfere with vaccine shedding and immune response⁵². Thus, in poorer regions where breastfeeding tends to be more common, concomitant breastfeeding could play a partial role in reducing the efficacy/effectiveness of the vaccine by neutralizing vaccine replication to some extent. Three field studies addressing this issue provide good evidence that the role of breastmilk in reducing vaccine immune responses is non-existent or minimal. In a well-designed trial in Pakistan, rotavirus IgA seroconversion rates and geometric mean titers were evaluated in vaccinated children randomly assigned to one of two groups, a group where breastfeeding was withheld for at least 1 hour before and after vaccination and a group where infants received at least 20 minutes of breastmilk at most 10 minutes before vaccination. Rather surprisingly, IgA seroconversion rates were roughly 10% higher in the group receiving breastmilk after both the first and the second dose. Hints of possible interference were observed in the antibody titers achieved, which were lower among seroresponders receiving breastmilk after the first dose compared to those not receiving milk; a subset of infants with low maternally derived antibodies receiving high-antibody-containing breastmilk seemed to have a reduced immune response⁵³. A similar study in Indian children in whom breastmilk was withheld for 30 minutes before and after vaccination, or encouraged, showed no differences in seroconversion rates; in this study, seroconversion rates were quite low in both groups (26–27%)⁵⁴. In a South African study with seroconversion rates near 60%, withholding breastmilk for 1 hour showed no difference compared to a breastmilk-encouraged group in anti-rotavirus IgA seroresponse rates or antibody titers achieved⁵⁵. Other factors are possible, such as the increased prevalence of severe malnutrition leading to reduced vaccine immune responses; however, this hypothesis is supported by only one relatively underpowered study⁵⁶.

Environmental enteropathy is a subclinical condition characterized by small intestine inflammation with shortened villi, intestinal barrier dysfunction, and reduced nutrient absorption. This condition seems to be common in children living in poor, unsanitary conditions and is thought to be caused by repeated or chronic exposure

to enteropathogens and by malnutrition⁵⁷. Studies using biomarkers associated with this condition show that it is present in over 80% of 12-week-old infants in Bangladesh⁵⁸. Using a complex model, this condition was reported to be associated with decreased seroresponse and failure of the vaccine Rotarix®. In children from El Salvador, this condition was also associated with lower seroresponse rates to RotaTeq®⁵⁹.

Lastly, differences in the gut microbiota/microbiome have been proposed as a factor affecting vaccine effectiveness; while regional differences exist⁶⁰, the potential that the gut microbiome plays any role in differential protection rates will require future studies, which are currently underway⁶¹. A recent publication is enlightening, as it shows that children from Ghana responding to rotavirus vaccination as determined by an anti-rotavirus IgA titer >20 IU/mL have a different microbiome profile compared to non-responders. Interestingly, responders had a microbiome profile more similar to a Dutch infant group compared to non-responders⁶².

Serotype replacement leading to an increase in non-vaccine serotypes over time, due to possible vaccine selective pressure, has been repeatedly postulated during the past decade, but it lacks robust supporting evidence. Increases in the predominance of specific rotavirus serotypes, heterotypic to the vaccines in use, have occurred, but mostly in a temporal manner similar to the known unpredictable regional and temporal variability of rotavirus serotype circulation observed before the vaccine era^{7,63}. The biological plausibility of a selective pressure phenomenon is low, as rotavirus vaccines do not abolish the circulation of any particular serotype (protection against infection does not surpass 60%) and “competition” between different serotypes within the intestine (as occurs for pneumococcus in the nasopharynx) is unlikely. Low-level emergence of “uncommon serotypes” such as G5, G8, G12⁶⁴, and the more significant G9 serotype, which emerged as a new, frequently predominant serotype during the past few decades, are ongoing phenomena which will most likely continue to occur with or without widespread vaccination. Because different vaccines are most likely not equally protective against all potential human serotypes, and because some novel serotypes may be more fit for the human intestine, it is possible that one or more of these less common types could prevail over others (relative predominance) for a given time period. Importantly, 10 years after vaccine introduction, the emergence of uncommon strains has been mild. A well-performed systematic literature review and meta-analysis including publications with content on rotavirus vaccine

effectiveness and strain characterization published from January 2006–2014 concluded that vaccines have similar effectiveness against partly or fully heterotypic strains compared with homotypic strains. It also concluded that the emergence of particular serotypes has not occurred after vaccination⁶⁵. Serotype surveillance will continue to be important, especially in low-income countries, where vaccines are less efficacious and data on rotavirus serotype distribution are scarce; importantly, the interpretation of serotype variations should be carried out with caution.

Further considerations of parenteral protein-based rotavirus vaccine candidates, if proven safe and efficacious, may be of benefit for several reasons. First, we could move away from any risk of intussusception, as it is unlikely that a parenteral vaccine would be a trigger. Second, theoretically any external interference with vaccine take (maternal antibodies, breastmilk, and live poliovirus) would be unlikely, with the potential for increased efficacy, although this is highly speculative at the moment. Third, a combination vaccine with another major cause of diarrhea, such as norovirus, could be considered; one current norovirus VLP and rotavirus VP6 nanostructure-based vaccine demonstrated an interesting adjuvant effect of the rotavirus component on norovirus immune response⁶⁶, although it is unclear if this would provide protection against rotavirus. Combination with rotavirus outer capsid proteins³⁹ may be a future avenue to explore.

Forty-five years after rotavirus discovery, extensive research efforts have led to safe and effective vaccines, which are reducing childhood deaths and suffering. It has been a success story, which is not over. Several pending issues have been discussed here, and the next decade should bring new insights, advances, and answers and, most importantly, significantly more children receiving rotavirus vaccines.

Competing interests

The author declares that he has no competing interests.

Grant information

The author(s) declared that no grants were involved in supporting this work.

Acknowledgements

The author thanks Anne Lagomarcino for her critical review and editing of the manuscript.

References

- Rodriguez WJ, Kim HW, Brandt CD, *et al.*: **Rotavirus gastroenteritis in the Washington, DC, area: incidence of cases resulting in admission to the hospital.** *Am J Dis Child.* 1980; **134**(8): 777–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Matson DO, Estes MK: **Impact of rotavirus infection at a large pediatric hospital.** *J Infect Dis.* 1990; **162**(3): 598–604.
[PubMed Abstract](#) | [Publisher Full Text](#)
- O’Ryan M, Pérez-Schael I, Mamani N, *et al.*: **Rotavirus-associated medical visits and hospitalizations in South America: a prospective study at three large sentinel hospitals.** *Pediatr Infect Dis J.* 2001; **20**(7): 685–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Parashar UD, Hummelman EG, Bresee JS, *et al.*: **Global illness and deaths caused by rotavirus disease in children.** *Emerg Infect Dis.* 2003; **9**(5): 565–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

5. Raúl Velázquez F, Calva JJ, Lourdes Guerrero M, *et al.*: **Cohort study of rotavirus serotype patterns in symptomatic and asymptomatic infections in Mexican children.** *Pediatr Infect Dis J.* 1993; 12(1): 54–61.
[PubMed Abstract](#)
6. O’Ryan ML, Matson DO, Estes MK, *et al.*: **Molecular epidemiology of rotavirus in children attending day care centers in Houston.** *J Infect Dis.* 1990; 162(4): 810–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. O’Ryan M: **The ever-changing landscape of rotavirus serotypes.** *Pediatr Infect Dis J.* 2009; 28(3 Suppl): S60–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Rojas AM, Boher Y, Guntiñas MJ, *et al.*: **Homotypic immune response to primary infection with rotavirus serotype G1.** *J Med Virol.* 1995; 47(4): 404–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Ward RL, Clemens JD, Knowlton DR, *et al.*: **Evidence that protection against rotavirus diarrhea after natural infection is not dependent on serotype-specific neutralizing antibody.** *J Infect Dis.* 1992; 166(6): 1251–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Offit PA, Hofferberg EJ, Santos N, *et al.*: **Rotavirus-specific humoral and cellular immune response after primary, symptomatic infection.** *J Infect Dis.* 1993; 167(6): 1436–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Angel J, Steele AD, Franco MA: **Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges.** *Hum Vaccin Immunother.* 2014; 10(12): 3659–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Kapikian AZ, Hoshino Y, Chanock RM, *et al.*: **Jennerian and modified Jennerian approach to vaccination against rotavirus diarrhea using a quadrivalent rhesus rotavirus (RRV) and human-RRV reassortant vaccine.** *Arch Virol Suppl.* 1996; 12: 163–75.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Clark HF, Bernstein DI, Dennehy PH, *et al.*: **Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants.** *J Pediatr.* 2004; 144(2): 184–90.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Joensuu J, Koskenniemi E, Pang XL, *et al.*: **Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis.** *Lancet.* 1997; 350(9086): 1205–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Santosham M, Moulton LH, Reid R, *et al.*: **Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations.** *J Pediatr.* 1997; 131(4): 632–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Pérez-Schael I, Guntiñas MJ, Pérez M, *et al.*: **Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela.** *N Engl J Med.* 1997; 337(17): 1181–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Murphy TV, Gargiulo PM, Massoudi MS, *et al.*: **Intussusception among infants given an oral rotavirus vaccine.** *N Engl J Med.* 2001; 344(8): 564–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Vesikari T, Matson DO, Dennehy P, *et al.*: **Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.** *N Engl J Med.* 2006; 354(1): 23–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. **F** Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, *et al.*: **Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.** *N Engl J Med.* 2006; 354(1): 11–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
20. O’Ryan M, Lucero Y, Linhares AC: **Rotarix®: vaccine performance 6 years postlicensure.** *Expert Rev Vaccines.* 2011; 10(12): 1645–59.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. **F** Jonesteller CL, Burnett E, Yen C, *et al.*: **Effectiveness of Rotavirus Vaccination: A systematic review of the first decade of global post-licensure data, 2006–2016.** *Clin Infect Dis.* 2017; 65(5): 840–850.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
22. **F** Leino T, Ollgren J, Strömberg N, *et al.*: **Evaluation of the Intussusception Risk after Pentavalent Rotavirus Vaccination in Finnish Infants.** *PLoS One.* 2016; 11(3): e0144812.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
23. **F** Haber P, Parashar UD, Haber M, *et al.*: **Intussusception after monovalent rotavirus vaccine—United States, Vaccine Adverse Event Reporting System (VAERS), 2008–2014.** *Vaccine.* 2015; 33(38): 4873–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
24. **F** Rosillon D, Buyse H, Friedland LR, *et al.*: **Risk of Intussusception After Rotavirus Vaccination: Meta-analysis of Postlicensure Studies.** *Pediatr Infect Dis J.* 2015; 34(7): 763–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
25. Vesikari T, Van Damme P, Giaquinto C, *et al.*: **European Society for Paediatric Infectious Diseases consensus recommendations for rotavirus vaccination in Europe: update 2014.** *Pediatr Infect Dis J.* 2015; 34(6): 635–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Indian Academy of Pediatrics, Advisory Committee on Vaccines and Immunization Practices (acvip), Vashishtha VM, Kalra A, *et al.*: **Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years, India, 2013 and updates on immunization.** *Indian Pediatr.* 2013; 50(12): 1095–108.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Lee PI, Chen PY, Huang YC, *et al.*: **Recommendations for rotavirus vaccine.** *Pediatr Neonatol.* 2013; 54(6): 355–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Cortese MM, Parashar UD, Centers for Disease Control and Prevention (CDC): **Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP).** *MMWR Recomm Rep.* 2009; 58(RR-2): 1–25.
[PubMed Abstract](#)
29. **Meeting of the immunization Strategic Advisory Group of Experts, April 2009—conclusions and recommendations.** *Wkly Epidemiol Rec.* 2009; 84(23): 220–36.
[PubMed Abstract](#)
30. Chandola TR, Taneja S, Goyal N, *et al.*: **ROTAVAC® does not interfere with the immune response to childhood vaccines in Indian infants: A randomized placebo controlled trial.** *Heliyon.* 2017; 3(5): e00302.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. **F** Bhandari N, Rongsen-Chandola T, Bavdekar A, *et al.*: **Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial.** *Lancet.* 2014; 383(9935): 2136–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
32. Fu C, He Q, Xu J, *et al.*: **Effectiveness of the Lanzhou lamb rotavirus vaccine against gastroenteritis among children.** *Vaccine.* 2012; 31(1): 154–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Yen C, Tate JE, Hyde TB, *et al.*: **Rotavirus vaccines: current status and future considerations.** *Hum Vaccin Immunother.* 2014; 10(6): 1436–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Dang DA, Nguyen VT, Vu DT, *et al.*: **A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children.** *Vaccine.* 2012; 30 Suppl 1: A114–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Naik SP, Zade JK, Sabale RN, *et al.*: **Stability of heat stable, live attenuated Rotavirus vaccine (ROTASIL®).** *Vaccine.* 2017; 35(22): 2962–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. **F** Isanaka S, Guindo O, Langendorf C, *et al.*: **Efficacy of a Low-Cost, Heat-Stable Oral Rotavirus Vaccine in Niger.** *N Engl J Med.* 2017; 376(12): 1121–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
37. Saluja T, Palkar S, Misra P, *et al.*: **Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): Randomized, controlled phase III study in Indian infants.** *Vaccine.* 2017; 35(28): 3575–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. **F** Bines JE, Danchin M, Jackson P, *et al.*: **Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial.** *Lancet Infect Dis.* 2015; 15(12): 1389–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
39. **F** Groome MJ, Koen A, Fix A, *et al.*: **Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.** *Lancet Infect Dis.* 2017; 17(8): 843–853.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
40. O’Ryan M, Lopman BA: **Parenteral protein-based rotavirus vaccine.** *Lancet Infect Dis.* 2017; 17(8): 786–787.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. GBD Diarrhoeal Diseases Collaborators: **Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015.** *Lancet Infect Dis.* 2017; pii: S1473-3099(17)30276-1.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. **F** Burnett E, Jonesteller CL, Tate JE, *et al.*: **Global Impact of Rotavirus Vaccination on Childhood Hospitalizations and Mortality from Diarrhea.** *J Infect Dis.* 2017; 215(11): 1666–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
43. Groome MJ, Page N, Cortese MM, *et al.*: **Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: a case-control study.** *Lancet Infect Dis.* 2014; 14(11): 1096–104.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. **F** Bar-Zeev N, Kapanda L, Tate JE, *et al.*: **Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study.** *Lancet Infect Dis.* 2015; 15(4): 422–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
45. O’Ryan ML, Clemens R: **Rotavirus vaccines roll-out in resource-deprived regions.** *Lancet Infect Dis.* 2015; 15(4): 368–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
46. Parashar UD, Johnson H, Steele AD, *et al.*: **Health Impact of Rotavirus Vaccination in Developing Countries: Progress and Way Forward.** *Clin Infect*

- Dis. 2016; **62 Suppl 2**: S91–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
47. Ricciardi GW, Toumi M, Weil-Olivier C, *et al.*: **Comparison of NITAG policies and working processes in selected developed countries.** *Vaccine*. 2015; **33**(1): 3–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
 48. Ricciardi GW, Toumi M, Poland G: **Recommendations for strengthening NITAG policies in developed countries.** *Vaccine*. 2015; **33**(1): 1–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Gladstone BP, Ramani S, Mukhopadhyay I, *et al.*: **Protective effect of natural rotavirus infection in an Indian birth cohort.** *N Engl J Med*. 2011; **365**(4): 337–46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 50. Ramani S, Mamani N, Villena R, *et al.*: **Rotavirus Serum IgA Immune Response in Children Receiving Rotarix Coadministered With bOPV or IPV.** *Pediatr Infect Dis J*. 2016; **35**(10): 1137–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 51. Vesikari T, Prymula R, Schuster V, *et al.*: **Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants.** *Pediatr Infect Dis J*. 2012; **31**(5): 509–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. **F** Bautista-Marquez A, Velasquez DE, Esparza-Aguilar M, *et al.*: **Breastfeeding linked to the reduction of both rotavirus shedding and IgA levels after Rotarix® immunization in Mexican infants.** *Vaccine*. 2016; **34**(44): 5284–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 53. **F** Ali A, Kazi AM, Cortese MM, *et al.*: **Impact of withholding breastfeeding at the time of vaccination on the immunogenicity of oral rotavirus vaccine—a randomized trial.** *PLoS One*. 2015; **10**(6): e0127622.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 54. Rongsen-Chandola T, Strand TA, Goyal N, *et al.*: **Effect of withholding breastfeeding on the immune response to a live oral rotavirus vaccine in North Indian infants.** *Vaccine*. 2014; **32 Suppl 1**: A134–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 55. Groome MJ, Moon SS, Velasquez D, *et al.*: **Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa.** *Bull World Health Organ*. 2014; **92**(4): 238–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 56. Gastañaduy PA, Steenhoff AP, Mokomane M, *et al.*: **Effectiveness of Monovalent Rotavirus Vaccine After Programmatic Implementation in Botswana: A Multisite Prospective Case-Control Study.** *Clin Infect Dis*. 2016; **62 Suppl 2**: S161–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. Korpe PS, Petri WA Jr: **Environmental enteropathy: critical implications of a poorly understood condition.** *Trends Mol Med*. 2012; **18**(6): 328–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 58. **F** Naylor C, Lu M, Haque R, *et al.*: **Environmental Enteropathy, Oral Vaccine Failure and Growth Faltering in Infants in Bangladesh.** *EBioMedicine*. 2015; **2**(11): 1759–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 59. **F** Becker-Dreps S, Vilchez S, Bucardo F, *et al.*: **The Association Between Fecal Biomarkers of Environmental Enteropathy and Rotavirus Vaccine Response in Nicaraguan Infants.** *Pediatr Infect Dis J*. 2017; **36**(4): 412–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 60. Magne F, O’Ryan ML, Vidal R, *et al.*: **The human gut microbiome of Latin America populations: a landscape to be discovered.** *Curr Opin Infect Dis*. 2016; **29**(5): 528–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
 61. Sindhu KN, Cunliffe N, Peak M, *et al.*: **Impact of maternal antibodies and infant gut microbiota on the immunogenicity of rotavirus vaccines in African, Indian and European infants: protocol for a prospective cohort study.** *BMJ Open*. 2017; **7**(3): e016577.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 62. **F** Harris VC, Armah G, Fuentes S, *et al.*: **Significant Correlation Between the Infant Gut Microbiome and Rotavirus Vaccine Response in Rural Ghana.** *J Infect Dis*. 2017; **215**(1): 34–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 63. **F** Luchs A, Cilli A, Morillo SG, *et al.*: **Rotavirus Genotypes Circulating in Brazil, 2007–2012: Implications for the Vaccine Program.** *Rev Inst Med Trop Sao Paulo*. 2015; **57**(4): 305–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 64. Gentsch JR, Laird AR, Bielfelt B, *et al.*: **Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs.** *J Infect Dis*. 2005; **192 Suppl 1**: S146–59.
[PubMed Abstract](#) | [Publisher Full Text](#)
 65. Leshem E, Lopman B, Glass R, *et al.*: **Distribution of rotavirus strains and strain-specific effectiveness of the rotavirus vaccine after its introduction: a systematic review and meta-analysis.** *Lancet Infect Dis*. 2014; **14**(9): 847–56.
[PubMed Abstract](#) | [Publisher Full Text](#)
 66. **F** Malm M, Heinimäki S, Vesikari T, *et al.*: **Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.** *Clin Exp Immunol*. 2017; **189**(3): 331–341.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 67. Giaquinto C, Dominiak-Felden G, Van Damme P, *et al.*: **Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries.** *Hum Vaccin*. 2011; **7**(7): 734–48.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. **F** Armah GE, Kapikian AZ, Vesikari T, *et al.*: **Efficacy, immunogenicity, and safety of two doses of a tetravalent rotavirus vaccine RRV-TV in Ghana with the first dose administered during the neonatal period.** *J Infect Dis*. 2013; **208**(3): 423–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 69. Bhandari N, Sharma P, Taneja S, *et al.*: **A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial.** *J Infect Dis*. 2009; **200**(3): 421–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 70. Danchin M, Kirkwood CD, Lee KJ, *et al.*: **Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine.** *Vaccine*. 2013; **31**(23): 2610–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 71. Luna EJ, Frazzatti-Gallina NM, Timenetsky MC, *et al.*: **A phase I clinical trial of a new 5-valent rotavirus vaccine.** *Vaccine*. 2013; **31**(7): 1100–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 72. O’Ryan M, Vidal R, del Canto F, *et al.*: **Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and *Vibrio cholerae*.** *Hum Vaccin Immunother*. 2015; **11**(3): 584–600.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Umesh Parashar**
CDC, Atlanta, GA, USA
Competing Interests: No competing interests were disclosed.
2. **Zulfiqar Bhutta**
The Hospital for Sick Children, Toronto, Ontario, Canada
Competing Interests: No competing interests were disclosed.
3. **Maarten J. Postma**
University of Groningen, Groningen, The Netherlands
Abrham Wondimu Dagne
Mekelle University, Mekelle, Ethiopia
Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research